You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JAK inhibitors

Showing 1 - 25 of 4,345
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Toxic Epidermal Necrolysis Trial in Fuzhou (Abrocitinib)

Recruiting
  • Toxic Epidermal Necrolysis
  • Fuzhou, Fujian, China
    Department of Dermatology, the First Affiliated Hospital of Fuji
Oct 31, 2023

Janus Kinase Inhibitors Vs Tumor Necrosis Factor Inhibitors in

Not yet recruiting
  • Rheumatoid Arthritis
  • Observation
  • (no location specified)
Oct 8, 2022

Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Abrocitinib 200 MG Oral Tablet
  • +2 more
  • (no location specified)
Feb 21, 2023

JAK Inhibition in Ulcerative Colitis

Not yet recruiting
  • Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
  • JAK inhibitor treatment
  • (no location specified)
Jul 11, 2022

JAK Inhibitors in Systemic Sclerosis-associated Interstitial

Recruiting
  • Systemic Sclerosis
  • Interstitial Lung Disease
    • Vandœuvre-lès-Nancy, Grand Est, France
      CHU Nancy
    Jan 19, 2022

    Rheumatoid Arthritis, Drug Use Trial in Hong Kong (biologic/targeted therapy)

    Not yet recruiting
    • Rheumatoid Arthritis
    • Drug Use
    • biologic/targeted therapy
    • Hong Kong, China
      Department of Medicine, Tuen Mun Hospital
    Jan 5, 2022

    Rheumatoid Arthritis Trial ("apigenin" and "glycyrrhizin", "glycyrrhizin" and "boswellic acid", "")

    Not yet recruiting
    • Rheumatoid Arthritis
    • "apigenin" and "glycyrrhizin"
    • +2 more
    • (no location specified)
    Mar 27, 2023

    Inpatient COVID-19 Treatments

    Active, not recruiting
    • COVID-19
    • Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
    • New York, New York
      Aetion, Inc.
    Jan 12, 2023

    Immunoclassification, Psoriasis Trial in Hangzhou (adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors,

    Recruiting
    • Immunoclassification
    • Psoriasis
    • adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
    • Hangzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Aug 16, 2022

    COVID 19, Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors Trial

    Withdrawn
    • COVID 19
    • Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors
    • (no location specified)
    Sep 8, 2021

    Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis

    Enrolling by invitation
    • Dermatitis, Atopic
      • Lisle-sur-Tarn, France
        Hop Claude Huriez Chu Lille
      May 27, 2021

      Rheumatoid Arthritis Trial in Montpellier (Ultrasound)

      Recruiting
      • Rheumatoid Arthritis
      • Ultrasound
      • Montpellier, France
        Rheumatology Department, Lapeyronie Hospital
      Jul 7, 2021

      Myelofibrosis Trial in Paris (Ruxolotinib)

      Completed
      • Myelofibrosis
      • Paris, France
        ROBIN
      Jul 26, 2022

      Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages

      Recruiting
      • Systemic Sclerosis
      • biological analysis
      • Rennes, France
        Rennes University Hospital
      Mar 17, 2021

      Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondyloarthritis Trial in Caba, Ciudad Autonoma Buenos Aires (DMARDs, biologic

      Recruiting
      • Arthritis, Rheumatoid
      • +2 more
      • Caba, Buenos Aires, Argentina
      • +1 more
      Mar 26, 2021

      Rheumatoid Arthritis, Inflammatory Rheumatism, Psoriatic Arthritis Trial in France (no intervention)

      Recruiting
      • Rheumatoid Arthritis
      • +3 more
      • no intervention
      • Antibes, France
      • +59 more
      Oct 25, 2022

      Rheumatoid Arthritis Trial in Montpellier (Blood sample analysis of patients treated as standard care)

      Recruiting
      • Rheumatoid Arthritis
      • Blood sample analysis of patients treated as standard care
      • Montpellier, France
        University Hospital of Montpellier
      Jan 12, 2022

      Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

      Recruiting
      • Arthritis, Rheumatoid
        • Sevilla, Spain
          Hospital Universitario Virgen macarena
        Nov 15, 2021

        Rheumatoid Arthritis, Healthy Controls Trial in Lund (Shingrix)

        Unknown status
        • Rheumatoid Arthritis
        • Healthy Controls
        • Shingrix
        • Lund, Sweden
          Skåne University hospital, Dept of rheumatology
        Apr 3, 2020

        Lupus or SLE, Nephritis Trial in Assiut (Baricitinib 4 MG, Baricitinib 2 MG, MMF)

        Recruiting
        • Lupus or SLE
        • Nephritis
        • Baricitinib 4 MG
        • +2 more
        • Assiut, Yes, Egypt
          Manal Hassanien
        Jan 13, 2023

        COVID-19 Trial in Chengdu (VV116+SOC, SOC)

        Recruiting
        • COVID-19
        • Chengdu, Sichuan, China
          Chengdu Zenitar Biomedical Technology Co., Ltd
        Feb 3, 2023

        Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual

        Terminated
        • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
        • +3 more
        • Houston, Texas
          M D Anderson Cancer Center
        Dec 1, 2020

        Vitiligo, Generalized Trial (Baricitinib)

        Not yet recruiting
        • Vitiligo, Generalized
        • (no location specified)
        Jul 7, 2023

        Acneiform Eruptions Trial in Shanghai (Cream containing JAK Inhibitor)

        Recruiting
        • Acneiform Eruptions
        • Cream containing JAK Inhibitor
        • Shanghai, Shanghai, China
          Shanghai East Hospital
        Jun 20, 2022

        Ulcerative Colitis, Thromboembolism Trial in Madrid (Tofacitinib, Infliximab Adalimumab y Golimumab)

        Recruiting
        • Ulcerative Colitis
        • Thromboembolism
        • Madrid, Spain
          Hospital Universitario de La Princesa
        Aug 2, 2022